Subcutaneous administration of a P2Y

1. A method for the prevention or treatment of a disease selected from acute coronary syndromes, myocardial infarction, peripheral ischaemia, amaurosis, sudden cardiac death, ischaemic stroke and transient ischaemic attack, the method comprising administering a pharmaceutically effective amount of a P2Y12 receptor antagonist, or a pharmaceutically acceptable salt thereof, to a patient in need thereof; wherein the P2Y 12 receptor antagonist is 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester; and wherein the P2Y 12 receptor antagonist is administered to the patient by intradermal or subcutaneous administration.

2. The method according to claim 1 , wherein the disease is selected from acute coronary syndromes and myocardial infarction.

3. The method according to claim 1 , wherein the P2Y12 receptor antagonist is administered prior to hospitalization.

4. The method according to claim 3 , wherein the P2Y12 receptor antagonist is administered by patient self-administration.

5. A method for the emergency treatment of suspected acute coronary syndromes, the method comprising administering a pharmaceutically effective amount of a P2Y12 receptor antagonist, or a pharmaceutically acceptable salt thereof, by patient self-administration prior to hospitalization; wherein the P2Y 12 receptor antagonist is 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester; and wherein the P2Y 12 receptor antagonist is administered to the patient by intradermal or subcutaneous administration.

6. The method according to claim 1 , wherein the P2Y 12 receptor antagonist is administered to a patient by subcutaneous administration.

7. The method according to claim 1 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is comprised between 1 mg and 75 mg per administration.

8. The method according to claim 1 , wherein the P2Y12 receptor antagonist is administered in a bolus injection.

9. The method according to claim 1 , wherein an inhibition of platelet aggregation of at least 75% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

10. A method for the emergency treatment of acute coronary syndromes by patient self-administration prior to hospitalization of a pharmaceutically active amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, wherein the method comprises the subcutaneous administration to the patient in need thereof.

11. The method according to claim 5 , wherein the P2Y 12 receptor antagonist is administered to a patient by subcutaneous administration.

12. The method according to claim 5 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is comprised between 1 mg and 75 mg per administration.

13. The method according to claim 5 , wherein the P2Y 12 receptor antagonist is administered in a bolus injection.

14. The method according to claim 5 , wherein an inhibition of platelet aggregation of at least 75% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

15. The method according to claim 2 , wherein the P2Y 12 receptor antagonist is administered prior to hospitalization.

16. The method according to claim 15 , wherein the P2Y 12 receptor antagonist is administered by patient self-administration.

17. The method according to claim 2 , wherein the P2Y 12 receptor antagonist is administered to a patient by subcutaneous administration.

18. The method according to claim 3 , wherein the P2Y 12 receptor antagonist is administered to a patient by subcutaneous administration.

19. The method according to claim 15 , wherein the P2Y 12 receptor antagonist is administered to a patient by subcutaneous administration.

20. The method according to claim 16 , wherein the P2Y 12 receptor antagonist is administered to a patient by subcutaneous administration.

21. The method according to claim 3 , wherein the amount of 44(R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is comprised between 1 mg and 75 mg per administration.

22. The method according to claim 15 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is comprised between 1 mg and 75 mg per administration.

23. The method according to claim 2 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is comprised between 5 mg and 35 mg per administration.

24. The method according to claim 3 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is comprised between 5 mg and 35 mg per administration.

25. The method according to claim 5 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is comprised between 5 mg and 35 mg per administration.

26. The method according to claim 19 , wherein the amount of 4(R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is comprised between 5 mg and 35 mg per administration.

27. The method according to claim 20 , wherein the amount of 4(R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is comprised between 5 mg and 35 mg per administration.

28. The method according to claim 10 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carb oxylic acid butyl ester that is administered is comprised between 5 mg and 35 mg per administration.

29. The method according to claim 2 , wherein the P2Y 12 receptor antagonist is administered in a bolus injection.

30. The method according to claim 3 , wherein the P2Y 12 receptor antagonist is administered in a bolus injection.

31. The method according to claim 26 , wherein the P2Y 12 receptor antagonist is administered in a bolus injection.

32. The method according to claim 27 , wherein the P2Y 12 receptor antagonist is administered in a bolus injection.

33. The method according to claim 28 , wherein the P2Y 12 receptor antagonist is administered in a bolus injection.

34. The method according to claim 2 , wherein an inhibition of platelet aggregation of at least 80% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

35. The method according to claim 3 , wherein an inhibition of platelet aggregation of at least 80% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

36. The method according to claim 5 , wherein an inhibition of platelet aggregation of at least 80% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

37. The method according to claim 19 , wherein an inhibition of platelet aggregation of at least 80% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

38. The method according to claim 20 , wherein an inhibition of platelet aggregation of at least 80% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

39. The method according to claim 26 , wherein an inhibition of platelet aggregation of at least 80% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

40. The method according to claim 27 , wherein an inhibition of platelet aggregation of at least 80% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

41. The method according to claim 28 , wherein an inhibition of platelet aggregation of at least 80% is reached within 30 min after onset of administration of the P2Y 12 receptor antagonist in at least 80% of the patients.

42. The method according to claim 2 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrim idine-4-carbonyl]-amino }-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is 16 mg per administration.

43. The method according to claim 3 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrim idine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is 16 mg per administration.

44. The method according to claim 5 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrim idine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is 16 mg per administration.

45. The method according to claim 17 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrim idine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is 16 mg per administration.

46. The method according to claim 19 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrim idine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is 16 mg per administration.

47. The method according to claim 20 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrim idine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is 16 mg per administration.

48. The method according to claim 10 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrim idine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is 16 mg per administration.

49. The method according to claim 34 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrim idine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is 16 mg per administration.

50. The method according to claim 36 , wherein the amount of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrim idine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered is 16 mg per administration.